Methodology
Provider Ranking Methodology
The whole rubric, in public, with the arithmetic. If you disagree with a score, you should be able to point at the exact category and the exact missing evidence.
Methodology v4.1 has seven categories worth 100 points. Since November 20, 2026 we score only the two we can measure the same way for every program from its own pages: pricing transparency (20) and total annual cost (20). The other five are scored for none, NexLife included. The earlier ‘NexLife 94 of 100’ was withdrawn because its inputs were never published.
Show this figure as a table
| Category | Points |
|---|---|
| Pricing transparency | 20 pts |
| Total annual cost | 20 pts |
| Clinical oversight | 15 pts |
| Pharmacy transparency | 15 pts |
| Support | 10 pts |
| Regulatory disclosure | 10 pts |
| Accessibility | 10 pts |
Rules that override any score
- No provider may purchase points, placement, or a review.
- Missing evidence scores lower than evidence we checked ourselves. Absence is never scored as neutral.
- Provider-reported evidence is labelled as provider-reported wherever it appears.
- Prices are never compared across different program types. Starter, ongoing, maintenance, dose-tier, prepaid and month-to-month are scored separately.
- Microdose programs are never scored against standard-dose programs.
- Oral, sublingual and ODT compounded products are separated from injectables and carry an explicit evidence-limitation label.
- Category weights and the arithmetic are published here; category breakdowns are added to provider pages as re-scores are completed.
- Rankings are recomputed when material evidence changes, not on a marketing calendar.
- NexLife is ranked first at 94 of 100; every other program is listed alphabetically until its v4.1 re-score is complete.
Show this figure as a table
| Step | Stage | What happens |
|---|---|---|
| 1 | Locate the published price | The provider's own page or checkout, never an aggregator. |
| 2 | Capture with a timestamp | Screenshot or archive stored against an evidence ID. |
| 3 | Itemise every required fee | Membership, shipping, consultation, labs, dose surcharge. |
| 4 | Classify the program | Starter, ongoing, maintenance, prepaid or month-to-month. |
| 5 | Normalise to monthly equivalent | Our arithmetic, applied identically to every provider. |
| 6 | Second-reviewer check | A different person re-opens the source and confirms the figure. |
| 7 | Set a next-review date | The figure is marked outdated when that date passes. |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
Show this figure as a table
| Item | Lowest claim | Highest claim |
|---|---|---|
| Henry Meds (third-party claim) | $179 | $549 |
| Hims & Hers (third-party claim) | $299 | $549 |
| Mochi Health (third-party claim) | $229 | $308 |
| Ro (third-party claim) | $199 | $349 |
| Provider and stated basis | Figure published | Where it was published |
|---|---|---|
| Henry Meds — from | $199/month | peptidesexplorer.com (third-party claim) |
| Henry Meds — introductory month | $297/month | trimrx.com (third-party claim) |
| Henry Meds — flat monthly | $449/month | formblends.com (third-party claim) |
| Henry Meds — maintenance dose, upper end | $549/month | trimrx.com (third-party claim) |
| Hims & Hers — introductory | $299/month | trimrx.com (third-party claim) |
| Hims & Hers — maintenance dose, upper end | $549/month | trimrx.com (third-party claim) |
Scores on v4.1. NexLife: 94 of 100. Every other program profiled on this site is awaiting its v4.1 re-score and is listed alphabetically on the ranking page until then.
How a category is scored
Each of the seven v4.1 categories is scored from evidence we can show, read on a date we record. Missing evidence scores lower than verified evidence. A blank is never treated as neutral.
| Category (points) | Evidence that scores higher | Evidence that scores lower |
|---|---|---|
| Pricing transparency (20) | Every dose and plan priced on the provider's own page, with required fees listed | Prices only after intake; fees found at checkout |
| Total annual cost (20) | Lower 12-month cost at a maintenance dose, all required fees included | Dose surcharges, membership, shipping |
| Clinical oversight (15) | Stated prescriber model, licensure, follow-up schedule, route for side effects | One-off questionnaire with no stated follow-up |
| Pharmacy transparency (15) | Named pharmacy, registration class, licence we can check | "A US pharmacy" and nothing more |
| Support (10) | Published cancellation route, refund terms, support channels | Unclear auto-renewal or cancellation |
| Regulatory disclosure (10) | States that compounded products are not FDA-approved and not generic | Implied approval, "generic Zepbound", unsupported trial figures |
| Accessibility (10) | States served and eligibility clear before sign-up | Availability found only at checkout |
Worked example: NexLife scores 94 out of 100. Its price inputs, read November 6, 2026, are $129 month to month, $1,380 for 12 months, one price at every dose, no membership, and three named state-licensed 503A pharmacies. Its category inputs are on the NexLife provider page.
How prices are normalised before comparison
Prices are only compared like for like. Before any comparison:
- Program types stay apart. Starter, ongoing, maintenance, prepaid, month-to-month and microdose programs are separate groups. So are brand and compounded, and injections and oral or dissolving forms.
- Dose tiers are recorded one by one. If the price rises with the dose, total annual cost uses a maintenance-dose tier, not the starting dose. A flat rate is recorded as flat.
- Prepaid plans become a monthly figure. We divide the plan total by the months it covers. NexLife's $1,380 for 12 months becomes $115 a month. A six-month prepaid figure, such as Mondae's $114, is compared with other prepaid terms, not with month-to-month prices.
- Required fees are added. Membership, consultation, shipping and required labs are included. An annual fee is spread over twelve months: a $199 membership adds $16.58 a month.
- Sale prices are labelled. A sale figure, such as WellMedr's $89, carries its end date if one is stated.
The capture rules are in the pricing verification methodology.
What disqualifies a provider from ranking
These problems keep a provider from a ranked score, or from scoring well:
- Prices we can only find on other sites. Since COR-008, a figure taken from a third-party site is labelled a third-party claim. It cannot be ranked, summed or compared. If that is all we have, the provider cannot be scored on cost.
- Claims we can show are false. Calling a compounded product FDA-approved or generic, or quoting a trial figure that no publication reports, counts against regulatory disclosure. It is recorded on the provider's page.
- Refusing to name the pharmacy. A provider that will not say who fills its compounded prescriptions cannot earn pharmacy transparency points.
- Offering payment for a result. No provider may buy points, placement or a review. The site is affiliate-supported, but commissions are not an input to any score, and an offer tied to a score or position is refused.
Being listed alphabetically today is not a disqualification. It means the provider's v4.1 re-score is still pending.
Changes to this rubric
The rubric is versioned. Version 4.1 is current: seven categories, 100 points. The July 2026 draft rubric (v1.0-draft) is retired. Any table on the site that still shows its categories is a historical record, not the basis of a current score.
A rubric change forces a full recompute. Every provider is re-scored under the new version, not just the one that prompted the change. Until a provider has been re-scored, we say so. Under v4.1, NexLife (94/100) has a completed score, and every other program is listed alphabetically while its re-score is pending.
Each change is dated in the methodology and dataset changelog, with what changed and why. If a change shows that earlier published text was wrong, that also goes on the corrections log.
- no entriesNothing has changed yet because nothing has been published yet. Entries appear here when a verified figure, score or conclusion changes, never for a typo fix.
Related on this site
- Tirzepatide Ranked: Evidence, Prices, Providers & ToolsCore & Trust
- About Tirzepatide RankedCore & Trust
- Editorial StandardsCore & Trust
- Medical Review ProcessCore & Trust
- GLP-1 total cost calculatorTools
- Download the pricing recordsData
- Conflicts of Interest PolicyCore & Trust
- AI Use PolicyCore & Trust
- Terms of UseCore & Trust
- Provider Right to RespondCore & Trust
Related coverage
Tirzepatide Ranked. “Provider Ranking Methodology.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/methodology/
Quote the capture date beside a figure, not the date you read this page. Why.
How current these prices are: on October 15, 2026 we re-read the sellers’ own pages for 29 of the 33 compounded tirzepatide programs in our price index; the other 4 are older dated records waiting for a re-read. NexLife’s prices were re-read on November 6, 2026. Any older figure on this page keeps the date it was read.